TAK 994
Alternative Names: TAK-994Latest Information Update: 28 May 2024
At a glance
- Originator Takeda
- Class Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Narcolepsy
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers) in USA (IV, Infusion)
- 28 May 2024 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers) in USA (PO, Suspension)
- 13 Apr 2024 Updated efficacy and adverse events data from a phase II trial in Narcolepsy presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)